Medical Crossfire®: Menin Inhibitors in AML—Dissecting the Data to Define the Role

Highlights from the PER® CME activity "Medical Crossfire®: Menin Inhibitors in AML—Dissecting the Data to Define the Role" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.

In this podcast, experts Naval Daver, MD; Courtney DiNardo, MD; and Eunice Wang, MD; discuss the rationale for treatment with menin inhibitors—and the data showing their efficacy and safety—in acute myeloid leukemia (AML).

Earn CME credit by completing the full accredited activity (available through March 17, 2027):
https://www.gotoper.com/courses/medical-crossfire-menin-inhibitors-in-amldissecting-the-data-to-define-the-role-3ng9

This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from Janssen Scientific Affairs, LLC, Kura Oncology, and Syndax Pharmaceuticals, Inc.

This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.